Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response

Cellular Immunology

Volumn 293, Issue 2, 2015, Pages 67-73

  Babolewska, Edyta ^a   Brzezińska Błaszczyk, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cathelicidins; Inflammation; Innate immunity; LL 37; Mast cells

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHEMOATTRACTANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDOLEUKOTRIENE; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR NECROSIS FACTOR; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CYSTEINE; CYSTEINYL-LEUKOTRIENE; CYTOKINE; LEUKOTRIENE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; RNA;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; INTRACELLULAR SIGNALING; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; CELL MOTION; CHEMISTRY; DEGRANULATION; FEMALE; GENETICS; IMMUNOLOGY; WISTAR RAT;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL DEGRANULATION; CELL MOVEMENT; CYSTEINE; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; LEUKOTRIENES; MAST CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION;

EID: 84920683764     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.12.006     Document Type: Article

References (42)

1. Weller C.L., Collington S.J., Williams T., Lamb J.R. Mast cells in health and disease. Clin. Sci. 2011, 120:473-484.
2. Rao K.N., Brown M.A. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann. NY Acad. Sci. 2008, 1143:83-104.
3. Maurer M., Theoharides T., Granstein R.D., Bischoff S.C., Bienenstock J., Henz B., Kovanen P., Piliponsky A.M., Kambe N., Vliagoftis H., Levi-Schaffer F., Metz M., Miyachi Y., Befus D., Forsythe P., Kitamura Y., Galli S. What is the physiological function of mast cells?. Exp. Dermatol. 2003, 12:886-910.
4. Theoharides T.C., Alysandratos K.D., Angelidou A., Delivanis D.A., Sismanopoulos N., Zhang B., Asadi S., Vasiadi M., Weng Z., Miniati A., Kalogeromitros D. Mast cells and inflammation. Biochim. Biophys. Acta 2012, 1822:21-33.
5. Metz M., Grimbaldeston M.A., Nakae S., Piliponsky A.M., Tsai M., Galli S.J. Mast cells in promotion and limitation of chronic inflammation. Immunol. Rev. 2007, 217:304-328.
6. St John A.L., Abraham S.N. Innate immunity and its regulation by mast cells. J. Immunol. 2013, 190:4458-4463.
7. Shelburne C.P., Abraham S.N. The mast cell in innate and adaptive immunity. Adv. Exp. Med. Biol. 2011, 716:162-185.
8. Sismanopoulos N., Delivanis D.A., Alysandratos K.D., Angelidou A., Therianou A., Kalogeromitros D., Theoharides T.C. Mast cells in allergic and inflammatory diseases. Curr. Pharm. Des. 2012, 18:2261-2277.
9. Anand P., Singh P.B., Jaggi A.S., Singh N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385:657-670.
10. Trivedi N.H., Guentzel M.N., Rodriguez A.R., Yu J.J., Forsthuber T.G., Arulanandam B.P. Mast cells: multitalented facilitators of protection against bacterial pathogens. Expert Rev. Clin. Immunol. 2013, 9:129-138.
11. Abraham S.N., St John A.L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 2010, 10:440-452.
12. Sandig H., Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front. Immunol. 2012, 3:185.
13. Munoz S., Hernandez-Pando R., Abraham S.N., Enciso J.A. Mast cell activation by Mycobacterium tuberculosis; mediator release and role of CD48. J. Immunol. 2003, 170:5590-5596.
14. Lima H.G., Pinke K.H., Gardizani T.P., Souza-Júnior D.A., Carlos D., Avila-Campos M.J., Lara V.S. Mast cells act as phagocytes against the periodontopathogen Aggregatibacter actinomycetemcomitans. J. Periodontol. 2013, 84:265-272.
15. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 2003, 170:2274-2278.
16. Di Nardo A., Yamasaki K., Dorschner R.A., Lai Y., Gallo R.L. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J. Immunol. 2008, 180:7565-7573.
17. Malaviya R., Twesten N.J., Ross E.A., Abraham S.N., Pfeifer J.D. Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J. Immunol. 1996, 156:1490-1496.
18. Frandji P., Oskéritzian C., Cacaraci F., Lapeyre J., Peronet R., David B., Guillet J.G., Mécheri S. Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J. Immunol. 1993, 151:6318-6328.
19. Lundequist A., Pejler G. Biological implications of preformed mast cell mediators. Cell. Mol. Life Sci. 2011, 68:965-975.
20. Vandamme D., Landuyt D.B., Luyten W., Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 2012, 280:22-35.
21. Choi K.Y., Chow L.N., Mookherjee N. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J. Innate Immun. 2012, 4:361-370.
22. Bowdish D.M., Davidson D.J., Hancock R.E. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol. 2006, 306:27-66.
23. Bucki R., Leszczyńska K., Namiot A., Sokołowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch. Immunol. Ther. Exp. (Warsz) 2010, 58:15-25.
24. Słodka A., Wiktorska M., Brzezińska-Błaszczyk E. IgE by itself affects mature rat mast cell preformed and de novo-synthesized mediator release and amplifies mast cell migratory response. PLoS One 2013, 8(10):e79286.
25. Babolewska E., Pietrzak A., Brzezińska-Błaszczyk E. Cathelicidin rCRAMP stimulates rat mast cells to cysteinyl leukotriene generation, TNF synthesis and migration: Involvement of PLC/A2, PI3K, and MAPK signaling pathways. Int. Immunol. 2014, 26:637-646.
26. Juremalm M., Olsson N., Nilsson G. Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4. Biochem. Biophys. Res. Commun. 2002, 297:480-485.
27. Kościuczuk E.M., Lisowski P., Jarczak J., Strzałkowska N., Jóźwik A., Horbańczuk J., Krzyz˙ewski J., Zwierzchowski L., Bagnicka E. Cathelicidins: family of antimicrobial peptides. Mol. Biol. Rep. 2012, 39:10957-10970.
28. Nijnik A., Hancock R.E. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr. Opin. Hematol. 2009, 16:41-47.
29. Yoshioka M., Fukuishi N., Kubo Y., Yamanobe H., Ohsaki K., Kawasoe Y., Murata M., Ishizumi A., Nishii Y., Matsui N., Akagi M. Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol. Pharm. Bull. 2008, 31:212-216.
30. Subramanian H., Gupta K., Guo Q., Price R., Ali H. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells resistance to receptor phosphorylation, desensitization, and internalization. J. Biol. Chem. 2011, 286:44739-44749.
31. Chen X., Niyonsaba F., Ushio H., Nagaoka I., Ikeda S., Okumura K., Ogawa H. Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J. Dermatol. Sci. 2006, 43:63-66.
32. Schiemann F., Brandt E., Gross R., Lindner B., Mittelstädt J., Sommerhoff C.P., Schulmistrat J., Petersen F. The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4. J. Immunol. 2009, 183:2223-2231.
33. Niyonsaba F., Someya A., Hirata M., Ogawa H., Nagaoka I. Evaluation of the effects of peptide antibiotics human β-defensins-1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells. Eur. J. Immunol. 2001, 31:1066-1075.
34. Niyonsaba F., Ushio H., Hara M., Yokoi H., Tominaga M., Takamori K., Kajiwara N., Saito H., Nagaoka I., Ogawa H., Okumura K. Antimicrobial peptides human β-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J. Immunol. 2010, 184:3526-3534.
35. Niyonsaba F., Iwabuchi K., Someya A., Hirata M., Matsuda H., Ogawa H., Nagaoka I. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002, 106:20-26.
36. Jeng L., Yamshchikov A.V., Judd S.E., Blumberg H.M., Martin G.S., Ziegler T.R., Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J. Transl. Med. 2009, 7:28.
37. Starner T.D., Agerberth B., Gudmundsson G.H., McCray P.B. Expression and activity of -defensins and LL-37 in the developing human lung. J. Immunol. 2005, 174:1608-1615.
38. Mandic Havelka A., Yektaei-Karin E., Hultenby K., Sørensen O.E., Lundahl J., Berggren V., Marchini G. Maternal plasma level of antimicrobial peptide LL37 is a major determinant factor of neonatal plasma LL37 level. Acta Paediatr. 2010, 99:836-841.
39. Davidopoulou S., Diza E., Sakellari D., Menexes G., Kalfas S. Salivary concentration of free LL-37 in edentulism, chronic periodontitis and healthy periodontium. Arch. Oral Biol. 2013, 58:930-934.
40. Xiao W., Hsu Y.P., Ishizaka A., Kirikae T., Moss R.B. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 2005, 128:2316-2326.
41. Chen C.I., Schaller-Bals S., Paul K.P., Wahn U., Bals R. Defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. 2004, 3:45-50.
42. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., Gallo R.L., Leung D.Y. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002, 347:1151-1160.